Alexander Urquhart, MD

Articles by Alexander Urquhart, MD

A Young Woman With a Small ER-Positive Breast Cancer, a Micrometastatic Axillary Lymph Node, and an Intermediate Oncotype DX Recurrence Score

ByDaniel W. Bowles, MD,Rachel Rabinovitch, MD,Virginia F. Borges, MD, MMSc,Alexander Urquhart, MD,Meenakshi Singh, MD,Christina A. Finlayson, MD,Anthony D. Elias, MD

September 1st 2007

patient is a 39-year-old premenopausal woman who presents with a new diagnosis of breast cancer to our multidisciplinary second opinion clinic.

A Woman With Primary Breast Cancer and a Solitary Sternal Metastasis

ByAlexander Menter, MD,Alexander Urquhart, MD,Virginia F. Borges, MD, MMSc,Rachel Rabinovitch, MD,Meenakshi Singh, MD,William Robinson, MD, PhD,Paul Seligman, MD,Christina A. Finlayson, MD,Anthony D. Elias, MD

August 1st 2006

The patient presented to her primary care physician 3 months prior with an inverted left nipple and a palpable lump that was highly suggestive of neoplasm on mammogram. An ultrasound-guided core biopsy revealed an infiltrating solid-type ductal carcinoma in situ. The estimated size of the mass was approximately 1 cm. She had no symptoms suggestive of metastatic disease.

Latest Updated Articles

A Young Woman With a Small ER-Positive Breast Cancer, a Micrometastatic Axillary Lymph Node, and an Intermediate Oncotype DX Recurrence Score
Published: September 1st 2007 | Updated:
A Woman With Primary Breast Cancer and a Solitary Sternal Metastasis
Published: August 1st 2006 | Updated:

Alexander Urquhart, MD

Articles by Alexander Urquhart, MD

A Young Woman With a Small ER-Positive Breast Cancer, a Micrometastatic Axillary Lymph Node, and an Intermediate Oncotype DX Recurrence Score

A Woman With Primary Breast Cancer and a Solitary Sternal Metastasis

Latest Updated Articles

Trending on CancerNetwork

FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

How ADCs are Replacing Chemotherapy as Breast Cancer Treatment

Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

What Do Physicians and Patients Think About ADCs as Cancer Treatment?